light anatom path
increas us anatom patholog presenc shl announc
acquisit aurora diagnost impli
ebitda multipl discount us patholog peer labcorp
trade aurora anatom patholog
provid us oper patholog practic across state
hospit contract shl fund acquisit
fulli underwritten institut placement per share
discount last close via share purchas plan
growth skew
anatom patholog provid organ growth stabl fund
us anatom patholog market highli fragment valu
grow mid-singl digit growth driven increas
preval chronic diseas grow age popul increas
healthcar expenditur
practic fund anatom patholog stabl versu clinic
patholog aurora revenu stream impact pama cut
cost synergi expect acquisit us
cost synergi evid acquisit see potenti revenu
synergi shl leverag new scale across hospit market
cross-sel base clinic patholog platform receiv
clariti manag quantiti potenti revenu synergi
factor forecast howev given highli fragment
anatom patholog market expect shl continu acquisit
us includ acquisit spend debt-fund
three year ebitda multipl
increas target price retain neutral rate
forecast acquisit ep accret
thereaft factor recent fx chang gener ep upgrad
across forecast period acquisit potenti driver
futur organ acquisit growth shl remain cautiou
mute level organ growth across group slower australian
patholog volum growth volatil germani post regul chang
valuat metric
chang previou ep
price month
total return forecast perspect
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price book
return equiti
return asset
return invest cap
net debt ebitda
capital-expenditure sale
capital-expenditure depr
price dec rate neutral target price analyst gretel janu
profit tax
profit tax
unusu item tax
chang work capit
cash non-cash item
movement cash/equival
 asx close
spot exchang rate
acquir aurora diagnost
shl announc acquisit aurora diagnost
impli ebitda multipl aurora anatom patholog provid us
pro-forma revenu ebitda sept
oper patholog practic hospit contract
view acquisit multipl fair discount us peer labcorp quest
diagnost trade key strateg benefit increas shl
scale us anatom patholog market
acquisit fund
fulli underwritten institut placement per share
discount last close
fulli underwritten acquisit bridg facil refinanc post
addit shl intend rais via non-underwritten share
purchas retail sharehold australian nz
anatom patholog branch patholog deal tissu diagnosi
diseas studi effect diseas structur bodi organ whole
mircroscop particular frequent use identifi manag variou
type tumor cancer
anatom patholog differ clinic patholog deal test blood
bodi fluid analysi blood cell
us anatom patholog market estim grow mid-
singl digit increas preval chronic diseas grow age popul
increas healthcar expenditur major factor drive growth
market anticip greater growth out-pati base practic hospit
contract often limit fix bed number compon
market fragment individu independ patholog player
aurora diagnost compris two divis
anatom patholog revenu consist out-pati base practic
refer physician greater hospit contract
repres anatom patholog revenu
alli servic revenu consist molecular gener
test aurora research institut potenti grow via data
aurora diagnost exposur cms/medicar fund
revenu impact pama cut
fund environ anatom patholog us current stabl
manag expect materi impact fee cut short-medium
impact shl
estim acquisit result ep accret thereaft
howev updat model recent fx chang result ep upgrad
across forecast period
shl re-affirm guidanc cc ebitda growth exclud
acquisit particular despit us peer recent downgrad earn softer
revenu perform shl state us busi oper ahead
expect shl base us busi forecast revenu growth
expect bolt-on acquisit us
factor cost synergi shl expand anatom vs
clinic patholog howev see potenti revenu synergi shl
leverag new scale across hospit market cross-sel clinic
patholog platform receiv quantif manag potenti
revenu synergi factor forecast
given fragment market expect shl continu acquisit us
factor bolt-on acquisit three year ebitda multipl
assum smaller bolt-on acquisit would debt fund forecast shl
net debt/ebitda decreas
increas target price impli tsr
howev anticip share price respond posit trade halt
lift view believ neutral rate appropri
figur us largest revenu segment
revenu segment
revenu growth segment
figur patholog largest segment
ebitda segment
ebitda segment mn
chart compani data credit suiss estim
new total return forecast perspect chart help visual credit suiss consensu view compani return within
context forecast risk histor trade pattern
volatil calcul annualis standard deviat weekli total return seri past month illustr variabl
stock return word risk way think one would rather take forecast return stock volatil
stock volatil shade area show one standard deviat rang base past month volatil statist
term make number brave assumpt probabl share price end insid rang month
hi-lo maximum minimum daili close price past week often handi know price momentum especi
stock trade close high low stock trade close peak momentum stock
consensu consensu suppli thomson reuter survey sell side research analyst collect dozen data
point ep dp sale target price roe mean averag target return shade area around mean
repres rang estim lowest highest estim aid visualis number import factor rang
analyst estim credit suiss estim stock sit rel consensu share price rel consensu
mean consensu rang target
return calcul capit gain plu forecast dividend yield net next month cs tgt use credit suiss
target price credit suiss forecast forward dividend gross frank consensu mean rang use
consensu target price consensu dividend forecast month forward
compani mention price
labcorp america lh
